Carlos Solorzano

Carlos Solórzano, PhD, is Principal on the Biotech Private Equity team at Ally Bridge Group, based in San Francisco, CA. In this role, he focuses on sourcing, leading, and managing investments in innovative biotechnology companies, leveraging deep sector expertise to identify and grow breakthrough platforms in therapeutics and life sciences.

Dr. Solórzano’s investment focus centers on the biotechnology and life sciences sectors, with a particular emphasis on private and growth-stage companies developing novel treatments and platforms. He has participated in and led investments in firms such as Akouos (acquired by Eli Lilly), Avalyn, Evommune, Plexium, Arkuda, Obsidian, and Nested Therapeutics, highlighting his track record in identifying high-potential ventures within biotech therapeutics.

Prior to Ally Bridge Group, Carlos held senior investment roles at Section 32 and Pivotal bioVenture Partners and was an Associate Director of corporate strategy and business development at Ultragenyx Pharmaceutical. He holds a PhD in pharmacology from UC Irvine, a BS in chemical engineering from Cal Poly Pomona, and completed an NIH postdoctoral fellowship at UC San Francisco, specializing in neurobiology research. His multifaceted career, spanning equity research, business development, and venture investing, underscores his significant contributions to the biotechnology investment ecosystem.